Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes?

Timothy M E Davis, Brett A Sillars and Wendy A Davis
Med J Aust 2009; 191 (6): . || doi: 10.5694/j.1326-5377.2009.tb02826.x
Published online: 21 September 2009

To the Editor: The ASPREE (ASPirin in Reducing Events in the Elderly) study may provide useful data on the benefits and risks of aspirin therapy in patients aged ≥ 70 years, as described by Woods and colleagues.1 However, the decision to allow general practitioner co-investigators to “help decide whether the patient is a suitable candidate for the placebo-controlled trial” introduces a source of selection bias that may limit the generalisability of the results. Without pre-specified objective selection criteria, it is likely that primary-prevention patients assessed by GP co-investigators as being at high vascular risk will be excluded because the GPs believe they should be taking antiplatelet agents. Similarly, those at low risk may be thought inappropriate participants because the risks of random allocation to this therapy might outweigh the perceived benefits, as has been shown in previous meta-analyses.2,3 ASPREE may end up with a disproportionate number of intermediate-risk patients.

  • Timothy M E Davis
  • Brett A Sillars
  • Wendy A Davis

  • School of Medicine and Pharmacology, University of Western Australia, Fremantle Hospital, Fremantle, WA.



remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.